Adenovirus Clinical Trial
Official title:
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
Verified date | October 2017 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
BACKGROUND:
The 243 amino acid E1A encoded by the left end of the human adenovirus (Ad) type 2 or 5
genome has been studied in various contexts including as a model cooperating oncoprotein , an
apoptosis inducing protein, and as a therapeutic oncolytic protein. All of these properties
are associated with its capacity to rapidly induce S phase in a variety of cells. E1A
orchestrates most of these effects by interacting with an array of chromatin remodeling
complexes, including the Rb family proteins, and the HAT proteins p300 and CBP.
The Myst family protein HBO1 (Myst2, KAT7) is a histone acetyl transferase that plays a major
role in replication initiation and also contributes to DNA re-replication. HBO1 directly
interacts with Cdt1 and functions as a coactivator of Cdt1 in replication initiation. It also
associates with replication origin and stimulates origin activation by acetylating H4 K5, K8,
and K12. Overexpression of HBO1 induces DNA re-replication.
SPECIFIC AIM OF THE STUDY: The Specific Aim of this study is to determine whether or not the
stimulation of HBO1 activity by E1A plays a role in deregulated DNA replication, and if it
does, to determine the mechanism.
1. Using standard assays the investigators will determine whether E1A binds to HBO1 to
induce its HAT activity
2. The investigators will determine whether E1A stimulation of HAT activity of HBO1
contributes to DNA re-replication.
RESEARCH DESIGN AND METHODS:
First, the investigators will determine whether E1A associates with replication origins and
whether this association requires HBO1. The investigators will use the MCM4 origin which maps
in the intergenic region between PRKDC and (Protein Kinase, DNA-Activated, Catalytic
Polypeptide) and MCM4 genes.
The investigators will transfect U2OS cells with plasmids expressing relevant proteins then
determine their occupancy in origin sequences using ChIP assays. Plasmids expressing epitope
tagged WT HBO1 or mutant derivatives along with plasmids expressing WT or mutant E1A proteins
will be expressed in U2OS cells, then occupancy of these proteins on origin regions will be
quantified using antibodies as appropriate. Typically in these experiments, using relevant
antibodies, ChIP assays are performed with primer pairs encompassing origin regions and also
regions that are far from origin. Occupancy of initiation factors are increased several fold
in the origin region as compared to that of 2KB upstream or downstream regions. Loading of
MCM complex along with Cdt1 onto the origins is an indication that initiation of replication
occurs in that origin and usually assayed in ChIP-re-ChIP assays as follows: First, loading
of HBO1 to the origins will be confirmed using epitope specific antibodies in the first ChIP.
The anti-HBO1 precipitates will be re-ChIPed with anti-MCM3 antibodies. Loading of MCM3
helicase to origins occurs after Cdt1 binding and depends on HBO1 HAT activity. Normal
amounts of MCM3 will be detected after re-ChIP-ing in E1A+ control samples. If reduced amount
of MCM3 is recovered in reChIP assays when mutant E1A or HBO1 mutant (e.g. HBO1 G435A) is
used, it would indicate that stimulation of HAT activity by E1A is critical for maximal
origin activity in E1A+ cells. This type of assay has considerable flexibility in that mutant
proteins can be rapidly assayed. This ChIP-reChiP assays will repeated in different
combinations to determine the E1A loading.
These results will be extended to virus infection assays. G1 specific cells isolated by drug
treatment will be infected with Ad vectors expressing epitope tagged proteins as appropriate.
Association of E1A and HBO1 and their mutant derivatives will be determined. This assay will
allow us to confirm the effect of E1A stimulated HAT activity in origin firing and study the
effects of E1A on origin firing, if any, other than increasing the HAT activity of HBO1.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | September 1, 2019 |
Est. primary completion date | September 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - All patients who are positive for adenovirus Exclusion Criteria: - immune comprised patients |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Heba Momen kamel |
Abbas T, Dutta A. CRL4Cdt2: master coordinator of cell cycle progression and genome stability. Cell Cycle. 2011 Jan 15;10(2):241-9. Epub 2011 Jan 15. Review. — View Citation
Abbas T, Shibata E, Park J, Jha S, Karnani N, Dutta A. CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Mol Cell. 2010 Oct 8;40(1):9-21. doi: 10.1016/j.molcel.2010.09.014. — View Citation
Aggarwal BD, Calvi BR. Chromatin regulates origin activity in Drosophila follicle cells. Nature. 2004 Jul 15;430(6997):372-6. — View Citation
Arias EE, Walter JC. Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. Genes Dev. 2007 Mar 1;21(5):497-518. Review. — View Citation
Avvakumov N, Côté J. Functions of myst family histone acetyltransferases and their link to disease. Subcell Biochem. 2007;41:295-317. Review. — View Citation
Baluchamy S, Rajabi HN, Thimmapaya R, Navaraj A, Thimmapaya B. Repression of c-Myc and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9524-9. Epub 2003 Jul 25. — View Citation
Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene. 2005 Nov 21;24(52):7673-85. Review. — View Citation
Breckenridge DG, Shore GC. Regulation of apoptosis by E1A and Myc oncoproteins. Crit Rev Eukaryot Gene Expr. 2000;10(3-4):273-80. Review. — View Citation
Brustel J, Tardat M, Kirsh O, Grimaud C, Julien E. Coupling mitosis to DNA replication: the emerging role of the histone H4-lysine 20 methyltransferase PR-Set7. Trends Cell Biol. 2011 Aug;21(8):452-60. doi: 10.1016/j.tcb.2011.04.006. Epub 2011 May 31. Review. — View Citation
DeCaprio JA. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology. 2009 Feb 20;384(2):274-84. doi: 10.1016/j.virol.2008.12.010. Epub 2009 Jan 17. Review. — View Citation
Deissler H, Opalka B. Therapeutic transfer of DNA encoding adenoviral E1A. Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):1-10. Review. — View Citation
Goren A, Tabib A, Hecht M, Cedar H. DNA replication timing of the human beta-globin domain is controlled by histone modification at the origin. Genes Dev. 2008 May 15;22(10):1319-24. doi: 10.1101/gad.468308. Epub 2008 Apr 28. — View Citation
Iizuka M, Matsui T, Takisawa H, Smith MM. Regulation of replication licensing by acetyltransferase Hbo1. Mol Cell Biol. 2006 Feb;26(3):1098-108. — View Citation
Kadeppagari RK, Sankar N, Thimmapaya B. Adenovirus transforming protein E1A induces c-Myc in quiescent cells by a novel mechanism. J Virol. 2009 May;83(10):4810-22. doi: 10.1128/JVI.02145-08. Epub 2009 Mar 11. — View Citation
Kolli S, Buchmann AM, Williams J, Weitzman S, Thimmapaya B. Antisense-mediated depletion of p300 in human cells leads to premature G1 exit and up-regulation of c-MYC. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4646-51. — View Citation
Lavia P, Mileo AM, Giordano A, Paggi MG. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene. 2003 Sep 29;22(42):6508-16. Review. — View Citation
Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology. 2009 Feb 20;384(2):285-93. doi: 10.1016/j.virol.2008.09.034. Epub 2008 Dec 11. Review. — View Citation
Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Adv Exp Med Biol. 2007;608:144-69. Review. — View Citation
Miotto B, Struhl K. HBO1 histone acetylase activity is essential for DNA replication licensing and inhibited by Geminin. Mol Cell. 2010 Jan 15;37(1):57-66. doi: 10.1016/j.molcel.2009.12.012. — View Citation
Miotto B, Struhl K. HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev. 2008 Oct 1;22(19):2633-8. doi: 10.1101/gad.1674108. — View Citation
Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev. 1993 Feb;3(1):63-70. Review. — View Citation
Rajabi HN, Baluchamy S, Kolli S, Nag A, Srinivas R, Raychaudhuri P, Thimmapaya B. Effects of depletion of CREB-binding protein on c-Myc regulation and cell cycle G1-S transition. J Biol Chem. 2005 Jan 7;280(1):361-74. Epub 2004 Nov 2. — View Citation
Saksouk N, Avvakumov N, Côté J. (de)MYSTification and INGenuity of tumor suppressors. Cell Mol Life Sci. 2008 Apr;65(7-8):1013-8. doi: 10.1007/s00018-008-7459-x. Review. — View Citation
Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene. 2008 Sep 25;27(43):5717-28. doi: 10.1038/onc.2008.181. Epub 2008 Jun 9. — View Citation
Sankar N, Kadeppagari RK, Thimmapaya B. c-Myc-induced aberrant DNA synthesis and activation of DNA damage response in p300 knockdown cells. J Biol Chem. 2009 May 29;284(22):15193-205. doi: 10.1074/jbc.M900776200. Epub 2009 Mar 30. — View Citation
Singhal G, Leo E, Setty SK, Pommier Y, Thimmapaya B. Adenovirus E1A oncogene induces rereplication of cellular DNA and alters DNA replication dynamics. J Virol. 2013 Aug;87(15):8767-78. doi: 10.1128/JVI.00879-13. Epub 2013 Jun 5. — View Citation
Smith JG, Wiethoff CM, Stewart PL, Nemerow GR. Adenovirus. Curr Top Microbiol Immunol. 2010;343:195-224. doi: 10.1007/82_2010_16. Review. — View Citation
Vogelauer M, Rubbi L, Lucas I, Brewer BJ, Grunstein M. Histone acetylation regulates the time of replication origin firing. Mol Cell. 2002 Nov;10(5):1223-33. — View Citation
* Note: There are 28 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DNA re-replication indicated by the number of cells containing >4N DNA content using flow cytometer | To determine whether E1A uses HBO1 in inducing re-replication by stimulating the HBO1 HAT activity, the investigators will infect S phase enriched cells (isolated by double thymidine block) with Ad viruses expressing the WT or mutant E1A proteins along with Ad vectors expressing HBO1 variants (e.g. HAT inactive), allow the infection to proceed as needed then quantify the population of cells containing >4N DNA content using flow cytometer. If E1A simulated HBO1 HAT activity is important for re-replication HAT defective HBO1 mutants will not induce re-replication even in the presence of E1A. E1A mutants that cannot bind to HBO1 will also show a similar phenotype. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Recruiting |
NCT03266627 -
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
|
Phase 2 | |
Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Completed |
NCT04056546 -
Interest of Rapid Typing in Adenovirus Infections.
|
||
Withdrawn |
NCT00448994 -
Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients
|
N/A | |
Recruiting |
NCT06299813 -
Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection
|
Phase 3 | |
Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
Terminated |
NCT02420080 -
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
|
N/A | |
Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
Completed |
NCT01535885 -
Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV
|
Phase 1 | |
Terminated |
NCT03339401 -
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
|
Phase 2 | |
Withdrawn |
NCT01584037 -
Adenovirus Vaccine Pregnancy Registry
|
N/A | |
Withdrawn |
NCT03532035 -
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
|
Phase 2 | |
Recruiting |
NCT02008812 -
Ad Sensor-based Real-time Diagnosis of Adenovirus
|
N/A | |
Active, not recruiting |
NCT04364178 -
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
|
Phase 1/Phase 2 | |
Recruiting |
NCT05664126 -
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
|
Phase 2 |